Article
Biology
Oana Belei, Diana-Georgiana Basaca, Elena Rodica Heredea, Emil Radu Iacob, Laura Olariu, Roxana Folescu, Andrei Gheorghe Marius Motoc, Anda-Maria Nanu, Otilia Marginean
Summary: VIPoma is a rare neuroendocrine tumor that produces vasoactive intestinal peptide (VIP). While rare in adults without pancreatic ailments, VIPoma originating in the pancreas is exceedingly uncommon in children. Instead, WDHA syndrome, characterized by watery diarrhea, hypokalemia, and achlorhydria, is more commonly associated with neurogenic tumors located in the retroperitoneum or mediastinum. Chronic diarrhea in infants is a prevalent issue that requires attention from pediatric gastroenterologists, and delays in diagnosis can lead to complications.
Article
Emergency Medicine
Daniel S. Tsze, Tamar R. Lubell, Robert C. Carter, Lauren S. Chernick, Kerrin C. DePeter, Son H. McLaren, Maria Y. Kwok, Cindy G. Roskind, Ariana E. Gonzalez, Weijia Fan, Shannon E. Babineau, Benjamin W. Friedman, Peter S. Dayan
Summary: This study aimed to compare the efficacy of intranasal ketorolac and intravenous ketorolac in reducing migraine headache pain in children. The results showed no significant difference between the two methods in pain reduction at 60 minutes, indicating that intranasal ketorolac was non-inferior to intravenous ketorolac for treating migraine pain in children.
ACADEMIC EMERGENCY MEDICINE
(2022)
Article
Biochemistry & Molecular Biology
Zhiqiang Zhang, Qi Li, Yongxiong Huang, Zhou Xu, Xinjin Chen, Baijian Jiang, Yu Huang, Jichang Jian
Summary: This study identified and characterized the VIP precursor gene and its receptor gene in Nile tilapia, and investigated their roles in immune modulation and protection against bacterial infection. The results showed that both genes were highly expressed in the intestine and induced by Streptococcus agalatiae. In vitro and in vivo experiments demonstrated immune functions of VIP, including inflammation suppression and promotion of apoptosis and pyroptosis.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Multidisciplinary Sciences
Rozalyn A. Simon, Nawroz Barazanji, Michael P. Jones, Olga Bednarska, Adriane Icenhour, Maria Engstrom, J. Paul Hamilton, Asa V. Keita, Susanna Walter
Summary: Plasma VIP levels are negatively correlated with symptoms of anxiety and depression, and positively correlated with functional connectivity and brain volume in specific brain regions associated with anxiety and depression.
SCIENTIFIC REPORTS
(2021)
Article
Medicine, General & Internal
Luregn J. Schlapbach, Kristen S. Gibbons, Stephen B. Horton, Kerry Johnson, Debbie A. Long, David H. F. Buckley, Simon Erickson, Marino Festa, Yves d'Udekem, Nelson Alphonso, David S. Winlaw, Carmel Delzoppo, Kim van Loon, Mark Jones, Paul J. Young, Warwick Butt, Andreas Schibler
Summary: The administration of nitric oxide into the gas flow of the cardiopulmonary bypass oxygenator does not significantly reduce ventilator-free days in children undergoing heart surgery. These findings suggest that the use of nitric oxide delivered into the cardiopulmonary bypass oxygenator may not be beneficial in improving respiratory recovery in these patients.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2022)
Article
Medicine, General & Internal
Elena Munoz-Gomez, Marta Ingles, Marta Aguilar-Rodriguez, Sara Molla-Casanova, Nuria Sempere-Rubio, Pilar Serra-Ano, Gemma V. Espi-Lopez
Summary: This study evaluated the effectiveness of a craniosacral therapy protocol on different features in migraine patients. The results showed that the therapy significantly reduced pain, frequency of episodes, functional and overall disability, and medication intake in migraine patients. The effects were maintained at follow-up evaluation, suggesting that this protocol may be a therapeutic approach for migraine patients.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Surgery
Fariba Abbassi, Sascha A. Mueller, Thomas Steffen, Bruno M. Schmied, Rene Warschkow, Ulrich Beutner, Ignazio Tarantino
Summary: This study aimed to evaluate whether caffeine could shorten the time to first bowel movement after laparoscopic colectomy. The results showed that caffeine was not associated with reduced time to first bowel movement.
BRITISH JOURNAL OF SURGERY
(2022)
Article
Clinical Neurology
Nadja Bredo Rasmussen, Christina Deligianni, Casper Emil Christensen, William Kristian Karlsson, Haidar Muhsen Al-Khazali, Tom Van de Casteele, Charlotte Granhall, Faisal Mohammad Amin, Messoud Ashina
Summary: Lu AG09222, an investigational humanized monoclonal antibody, inhibits PACAP38-induced vasodilation and headache, suggesting its potential as a therapy for PACAP-mediated diseases such as migraine.
JOURNAL OF HEADACHE AND PAIN
(2023)
Article
Integrative & Complementary Medicine
Seyoung Kim, Jihye Seo, Cheol-hyun Kim, Hyun-Kyung Sung, Ho-Yeon Go, Woo Sang Jung, Seungwon Kwon, Minjung Kwak, Sangkwan Lee
Summary: The study found that the herbal medicine Jodeungsan did not have a significant effect on chronic migraine, but there were significant improvements in headache impact and migraine-specific quality of life. Larger studies are needed to confirm these results.
INTEGRATIVE MEDICINE RESEARCH
(2022)
Article
Clinical Neurology
Samira Khani, Seyed Amir Hejazi, Mehdi Yaghoubi, Ehsan Sharifipour
Summary: The study assessed the efficacy of concurrent magnesium-sodium valproate therapy in comparison to magnesium or sodium valproate alone in migraine prophylaxis. Results showed that magnesium enhances the antimigraine properties of sodium valproate and reduces the required valproate dose for migraine prophylaxis.
JOURNAL OF HEADACHE AND PAIN
(2021)
Article
Medicine, General & Internal
Richard B. Lipton, Patricia Pozo-Rosich, Andrew M. Blumenfeld, David W. Dodick, Peter McAllister, Ye Li, Kaifeng Lu, Brett Dabruzzo, Rosa Miceli, Lawrence Severt, Michelle Finnegan, Joel M. Trugman
Summary: This study examined the efficacy and safety of atogepant for the preventive treatment of migraine. It found that atogepant significantly reduced mean monthly migraine-day (MMD) at all responder threshold levels during the 12-week treatment period. Higher doses of atogepant appeared to be more effective.
Article
Emergency Medicine
Sinem Dogruyol, Sultan Tuna Akgol Gur, Ilker Akbas, Meryem Betos Kocak, Abdullah Osman Kocak, Mustafa Ceylan, Davut Tekyol
Summary: This study compared the efficacy of sodium valproate and ibuprofen in the treatment of acute migraine attacks. The results showed that sodium valproate was superior to ibuprofen in relieving pain, with a significantly higher number of patients achieving the primary endpoint.
AMERICAN JOURNAL OF EMERGENCY MEDICINE
(2022)
Article
Medicine, General & Internal
Vittorio Sciruicchio, Daniela D'Agnano, Livio Clemente, Alessandra Rutigliano, Anna Laporta, Marina de Tommaso
Summary: Primary headaches, especially migraines, have a significant impact on the physical and mental health of children and adolescents. Osmophobia can be a potential marker for diagnosing and assessing disability in individuals with migraines. This study found that osmophobia was present in 28.8% of individuals with primary headaches, with a higher prevalence in children suffering from migraines. Migraine patients with osmophobia also showed more severe clinical symptoms, including enhanced disability and psychological distress.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Clinical Neurology
Rushil Shah, Fabrizio Assis, Bharat Narasimhan, Vahe Khachadourian, Shijie Zhou, Harikrishna Tandri, Nauman Tariq
Summary: Intranasal high-flow dry gas therapy may play a role in reducing migraine associated pain. Compared to humidified air, treatment with dry oxygen, dry air, and humidified oxygen showed significant reductions in pain and photosensitivity scores, indicating potential benefits for migraine relief.
Article
Medicine, Research & Experimental
Yasmine Hoydonckx, Mandeep Singh, Ian Gilron, James Khan, Samer Narouze, Albert Dahan, Kathryn Curtis, Xingshan Cao, Jamal Kara, Anuj Bhatia
Summary: This trial aims to evaluate the effect of high-dose IV ketamine infusions on chronic daily headaches. The results may provide a safe, affordable, and widely available treatment option for patients with refractory headaches.
Article
Anesthesiology
Janu Thuraiaiyah, Mohammad Al-Mahdi Al-Karagholi, Fatima Azzahra Elbahi, Zixuan Alice Zhuang, Messoud Ashina
Summary: In a randomized, double-blinded, placebo-controlled, crossover study, researchers found that adenosine does not significantly induce migraine attacks but does cause headache. Adenosine increases heart rate, facial skin blood flow, and superficial temporal artery diameter, while decreasing middle cerebral artery blood flow.
Review
Clinical Neurology
Mi Ji Lee, Mohammad Al-Mahdi Al-Karagholi, Uwe Reuter
Summary: This article reviews the use of monoclonal antibodies against calcitonin gene-related peptide (CGRP) or its receptor (anti-CGRP(-R) mAbs) and small-molecule CGRP receptor antagonists (gepants) in specific situations, such as non-responders to prior therapy, combination therapy, switching, and treatment termination. The evidence supports the use of all available anti-CGRP(-R) mAbs in non-responders to prior therapy. There is insufficient evidence to support or reject the efficacy of combining CGRP(-R) mAbs or gepants with oral migraine prophylactic agents or botulinum toxin A. Switching from one CGRP(-R) mAb to another might benefit a fraction of patients. Currently, treatment termination depends on reimbursement policies, and the optimal mode of termination is discussed.
Article
Clinical Neurology
Messoud Ashina, Caroline Roos, Lily Qian Li, Mika Komori, David Ayer, Dustin Ruff, John Henry Krege
Summary: During the 12-month extension study, patients treated with lasmiditan showed significant improvements in migraine-related disability and quality of life. No new safety concerns were identified.
Article
Clinical Neurology
Stewart J. Tepper, Richard B. Lipton, Stephen D. Silberstein, David Kudrow, Messoud Ashina, Uwe Reuter, David W. Dodick, Andrea Wang, Sunfa Cheng, Jan Klatt, Daniel D. Mikol
Summary: This study evaluated the long-term efficacy and safety of erenumab in patients with chronic migraine. The results showed that long-term treatment with erenumab could consistently reduce monthly migraine days and the efficacy was similar in patients with and without acute medication overuse.
Review
Clinical Neurology
Mohammad Al-Mahdi Al-Karagholi, Veberka Kalatharan, Hashmat Ghanizada, Gregory Dussor, Messoud Ashina
Summary: The review aimed to investigate the role of prolactin signaling in the pathophysiology of headache and migraine. Sex-dependent features of migraines suggest the involvement of the hypothalamus-pituitary-gonadal axis. Prolactin signaling has been implicated in sex-related differences in pain perception.
Article
Clinical Neurology
Christina Deligianni, Lanfranco Pellesi, Basit Ali Chaudhry, Anne Luise Haulund Vollesen, Agneta Henriette Snoer, Jens Hannibal, Rigmor Hojland Jensen, Messoud Ashina
Summary: In this study, the researchers investigated the effects of PACAP and VIP on plasma levels of VIP and their contribution to induced cluster headache attacks. The results showed a significant increase in plasma VIP levels during PACAP infusion in individuals with episodic cluster headache, but not in those with chronic cluster headache. Further studies are needed to understand the role of VIP and the parasympathetic system in cluster headache.
FRONTIERS IN NEUROLOGY
(2023)
Article
Clinical Neurology
Thien Phu Do, Christina Deligianni, Sarkhan Amirguliyev, Josefin Snellman, Cristina Lopez Lopez, Mohammad Al-Mahdi Al-Karagholi, Song Guo, Messoud Ashina
Summary: This study found that migraine attacks can be triggered by cAMP-mediated mechanisms without the activation of CGRP receptors. This opens up new possibilities for the development of mechanism-based drugs for the treatment of migraines.
Article
Clinical Neurology
Nadja Bredo Rasmussen, Christina Deligianni, Casper Emil Christensen, William Kristian Karlsson, Haidar Muhsen Al-Khazali, Tom Van de Casteele, Charlotte Granhall, Faisal Mohammad Amin, Messoud Ashina
Summary: Lu AG09222, an investigational humanized monoclonal antibody, inhibits PACAP38-induced vasodilation and headache, suggesting its potential as a therapy for PACAP-mediated diseases such as migraine.
JOURNAL OF HEADACHE AND PAIN
(2023)
Review
Clinical Neurology
R. Messina, R. H. Christensen, I. Cetta, M. Ashina, M. Filippi
Summary: This systematic review provides a comprehensive overview of the mechanisms of actions of headache treatments and potential biomarkers of treatment response revealed by neuroimaging studies. The findings suggest that acupuncture, neuromodulation, and medication withdrawal therapies can improve headache by altering headache-affected brain areas. However, there is currently no clear evidence for the specific location of action for each treatment and no reliable imaging predictors of efficacy.
JOURNAL OF HEADACHE AND PAIN
(2023)
Correction
Clinical Neurology
Faisal Mohammad Amin, Roberto De Icco, Mohammad Al-Mahdi Al-Karagholi, Jayachandra M. Raghava, Frauke Wolfram, Henrik B. W. Larsson, Messoud Ashina
JOURNAL OF HEADACHE AND PAIN
(2023)
Article
Clinical Neurology
Thien Phu Do, Mikala Domgaard, Simon Stefansen, Timothy J. Steiner, Messoud Ashina
Summary: This study aims to characterize healthcare utilization patterns of headache patients in Denmark. The results showed that a quarter of patients who were able to manage their headaches had never consulted a doctor. Additionally, some patients used opioids for headache treatment. Therefore, there is a need for increased public education and awareness, as well as policy adjustments to better address the burden of headache diseases on the population's health.
JOURNAL OF HEADACHE AND PAIN
(2023)
Article
Clinical Neurology
Messoud Ashina, Richard B. Lipton, Jessica Ailani, Jan Versijpt, Simona Sacco, Dimos D. Mitsikostas, Cecilie Laurberg Christoffersen, Bjorn Sperling, Anders Ettrup
Summary: This post hoc analysis suggests that eptinezumab can reduce monthly migraine days in patients with difficult-to-treat migraines. The majority of patients who responded to eptinezumab during the initial weeks maintained or improved their response during the later weeks. Additionally, a significant number of initial non-responders showed a response after the second infusion.
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Article
Clinical Neurology
Messoud Ashina, Dimos D. Mitsikostas, Verena Ramirez Campos, Steve Barash, Xiaoping Ning, Hans-Christoph Diener
Summary: This study aimed to determine the number needed to treat (NNT), number needed to harm (NNH), and likelihood of being helped or harmed (LHH) in a post hoc analysis of the phase 3b FOCUS trial. The results showed that the NNT, NNH, and LHH for quarterly and monthly fremanezumab compare favorably with those for traditional oral preventive medications, including topiramate, valproate, and propranolol.